Create Free Account

By creating account you will get access to hot stocks & personalised emails

Botanix Pharmaceuticals Ltd

Healthcare AU BOT

0.235AUD
0.01(6.82%)

Last update at 2024-05-01T06:10:00Z

Day Range

0.210.23
LowHigh

52 Week Range

0.080.24
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -9.15397M -13.17075M -3.33400M -16.73071M -17.03921M
Minority interest - - - - -
Net income -9.15397M -13.17075M -10.27537M -24.18044M -17.05042M
Selling general administrative 3.04M 3.56M 2.24M 8.25M 3.19M
Selling and marketing expenses - - - - -
Gross profit -5.62456M 0.10M - - -11.94435M
Reconciled depreciation 0.11M 0.14M 0.09M 0.10M 0.00158M
Ebit -9.07224M -13.13331M -3.27806M -16.67973M -17.02801M
Ebitda -8.96180M -12.98981M -3.18384M -16.57745M -17.02642M
Depreciation and amortization 0.11M 0.14M 0.09M 0.10M 0.00158M
Non operating income net other - - - - -
Operating income -9.12634M -13.13331M -3.27806M -16.67973M -17.02801M
Other operating expenses -1.45557M 15.94M 10.27M 24.26M 21.46M
Interest expense 0.08M 0.04M 0.06M 0.05M 0.01M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.09M 0.04M 0.06M 0.22M 0.00524M
Net interest income -0.01578M -0.00007M 0.05M -0.05098M 0.11M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.74M 2.81M 6.94M 7.45M 0.01M
Total revenue 0.10M 0.10M 0.10M 0.18M 0.19M
Total operating expenses 12.90M 15.94M 10.27M 24.26M 21.46M
Cost of revenue 5.73M - - - 16.63M
Total other income expense net 3.66M 2.77M -0.05594M -0.05098M -0.01121M
Discontinued operations - - - - -
Net income from continuing ops -9.15397M -13.17075M -3.33400M -16.73071M -17.03921M
Net income applicable to common shares -9.15397M -13.17075M -3.33400M -16.73071M -17.03921M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 24.84M 14.04M 21.95M 25.31M 5.20M
Intangible assets 10.73M 3.30M 3.30M - -
Earning assets - - - - -
Other current assets 0.09M 0.03M 0.00992M 0.00147M -
Total liab 1.88M 5.89M 1.15M 1.67M 4.58M
Total stockholder equity 22.95M 8.15M 20.80M 23.64M 0.62M
Deferred long term liab 3.87M - - - -
Other current liab 0.49M 1.20M 0.39M 0.37M 0.10M
Common stock 93.49M 71.48M 71.48M 71.41M 33.89M
Capital stock 93.49M 71.48M 71.48M 71.41M 33.89M
Retained earnings -76.92193M -67.76796M -54.59721M -51.26321M -34.53250M
Other liab - - - - -
Good will - - - - -
Other assets 3.94M 0.06M 0.06M 0.09M -
Cash 10.25M 7.29M 21.55M 24.65M 4.70M
Cash and equivalents - - - - -
Total current liabilities 1.88M 5.89M 1.04M 1.38M 4.58M
Current deferred revenue - -1.10828M -0.14714M -0.12433M -0.12433M
Net debt -10.25039M -7.16324M -21.29559M -24.22456M -4.28383M
Short term debt 0.00000M 0.12M 0.15M 0.12M 0.12M
Short long term debt - - - - -
Short long term debt total - 0.12M 0.26M 0.42M 0.42M
Other stockholder equity -16.56773M -3.70781M -16.87855M -20.15115M 1.26M
Property plant equipment 0.07M 0.18M 0.28M 0.45M 0.01M
Total current assets 13.98M 10.50M 21.61M 24.78M 5.19M
Long term investments - 0.06M 0.06M 0.09M -
Net tangible assets 16.10M 4.86M 20.80M 23.64M 0.62M
Short term investments - - - - 0.00000M
Net receivables 0.49M 0.14M 0.05M 0.13M 0.48M
Long term debt - - - - -
Inventory 3.15M 3.04M 3.04M - -
Accounts payable 1.39M 5.67M 0.65M 1.01M 4.48M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 6.38M 4.44M 3.92M 3.49M 1.26M
Additional paid in capital - - - - -
Common stock total equity - - - 71.41M 33.89M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.06M 0.06M - -0.08873M
Deferred long term asset charges - - - - -
Non current assets total 10.86M 3.54M 0.34M 0.53M 0.01M
Capital lease obligations - 0.12M 0.26M 0.42M -
Long term debt total 0.00000M 0.00000M 0.11M 0.30M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -7.05372M -2.92187M -0.00828M -0.15119M -0.01329M
Change to liabilities -4.03868M 4.65M -0.38174M -3.40955M 3.12M
Total cashflows from investing activities -7.05372M -2.92187M -0.00828M -0.15119M -0.01329M
Net borrowings -0.12241M -0.15241M -0.12550M -0.02308M -0.02308M
Total cash from financing activities 22.03M -0.15241M -0.12550M 37.31M 0.57M
Change to operating activities - - - - -
Net income -9.15397M -13.17075M -3.33400M -16.73071M -17.05042M
Change in cash 2.96M -14.26925M -3.09028M 19.94M -12.55895M
Begin period cash flow 7.29M 21.55M 24.65M 4.70M 17.26M
End period cash flow 10.25M 7.29M 21.55M 24.65M 4.70M
Total cash from operating activities -12.07406M -11.18406M -2.96802M -17.35859M -13.14072M
Issuance of capital stock 23.59M - - 40.49M 0.60M
Depreciation 0.11M 0.14M 0.09M 0.10M 0.00158M
Other cashflows from investing activities - - 0.00000M -0.06114M -0.06114M
Dividends paid -1.84924M 20.30M - - -
Change to inventory -0.10268M -3.04435M -3.04435M -3.04435M -3.04435M
Change to account receivables -0.40999M -0.09680M 0.09M 0.35M -0.05663M
Sale purchase of stock -1.43836M -1.43836M 0.00000M -3.15873M -0.02676M
Other cashflows from financing activities 3.58M -0.15241M -0.12550M -0.02308M -0.01329M
Change to netincome 1.52M 1.84M 0.57M 2.33M 0.84M
Capital expenditures 7.05M 2.92M 0.00828M 0.09M 0.01M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.51267M -3.14114M 0.09M 0.35M 4.81M
Stock based compensation 1.52M 0.33M 0.57M 2.33M -
Other non cash items -3.03052M 1.84M 0.27M -0.73016M 17.04M
Free cash flow -19.12778M -14.10592M -2.97630M -17.44864M -13.15401M

Fundamentals

  • Previous Close 0.22
  • Market Cap341.81M
  • Volume4195251
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.02176M
  • Revenue TTM0.44M
  • Revenue Per Share TTM-
  • Gross Profit TTM -1.95513M
  • Diluted EPS TTM-0.01

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BOT
Botanix Pharmaceuticals Ltd		 0.01 6.82% 0.23 - - 756.56 7.11 3383.55 -31.706
CSL
CSL Ltd		 -2.27 0.82% 274.49 35.08 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 -0.38 2.52% 14.67 763.75 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 -0.14 0.73% 19.06 16.04 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 0.11 11.11% 1.10 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.

Botanix Pharmaceuticals Ltd

D2, 661 Newcastle Street, Leederville, WA, Australia, 6007

Key Executives

Name Title Year Born
Mr. Vincent P. Ippolito MD & Exec. Chairman 1959
Dr. Howie McKibbon Chief Operating Officer NA
Dr. Henry William Bosch BA, Ph.D. Chief Scientific Officer & Exec. Director NA
Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB Exec. Director 1973
Dr. Clarence L. Young M.D. Chief Medical Officer 1956
Ms. Lynda Berne Head of Commercial NA
Dr. Jack Hoblitzell Ph.D. Sr. VP of Pharmaceutical Devel. NA
Dr. Patricia S. Walker M.D., Ph.D. Chief Medical Adviser 1959
Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA Company Sec. NA
Mr. Vincent P. Ippolito MD & Executive Chairman 1959

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.